Emilie Kristine Dahl

7PUBLICATIONS
25CO-AUTHORS
AutoimmunityPredictive and prognostic markersRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 14, 2025
Risk of Colitis in Patients With Inflammatory Bowel Disease or Microscopic Colitis Exposed to Checkpoint Inhibitors: A National Danish Cohort Study.

Emilie Kristine Dahl, Katrine Risager Christensen, Henrik Albæk Jacobsen

|May 20, 2025
Serum biomarkers of collagen remodeling are associated with intestinal fibrosis and differentiate stenotic from luminal Crohn's disease patients: a pre- and post-resection longitudinal study.

Anja Poulsen, Marta Sorokina Alexdóttir, Lene Buhl Riis

|Mar 23, 2023
Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours-Authors' reply.

Emilie Dahl, Osama Abed, Jørgen Agnholt

|Jan 22, 2023
Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases.

Sigrun Grimsdottir, Mohamed Attauabi, Emilie Kristine Dahl

|Dec 29, 2022
Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report.

Rikke Boedker Holmstroem, Emilie Kristine Dahl, Morten Helms

|Dec 05, 2022
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis-authors' reply.

Emilie K Dahl, Osama K Abed, Jens Kjeldsen

Pageof 2

Frequent Collaborators

3 joint publications

Jakob Benedict Seidelin

2 joint publications

Inge Marie Svane

2 joint publications

Johan Burisch

1 joint publications

Marco Donia